MTOR and tuberous sclerosis: Everolimus is an oral mTOR inhibitor derived from sirolimus, which had been approved by FDA in the treatment of patients with TSC-AML and adult patients with TSC-subependymal giant cell astrocytoma44, and the improved pharmacokinetic profile of everolimus over sirolimus makes it an attractive, noninvasive option for patients.